CMG Pharmaceutical lowers conversion price to ₩17,290 on share price decline
CMG Pharmaceutical adjusted its conversion price from ₩17,770 to ₩17,290, effective Nov 11, 2026, citing a conversion price adjustment due to share price decline. The number of shares issuable on conversion rose from 422,172 shares to 433,892 shares.
Key facts
| Price before adjustment | ₩17,770 |
|---|---|
| Price after adjustment | ₩17,290 |
| Shares before adjustment | 422,172 shares |
| Shares after adjustment | 433,892 shares |
| Reason | Conversion price adjustment due to share price decline |
| Effective date | Nov 11, 2026 |
| Increase in shares issuable (calculated) | 2.8% |
Comparison
| Revenue 2025 | ₩105.2bn |
|---|---|
| Revenue 2024 | ₩99.1bn |
| Revenue 2023 | ₩93.9bn |
Context
In the 12 months before this filing, the company recorded 1 CB/BW/EB issuance of ₩45.0bn and 1 conversion price adjustment, with potential new shares of 48,277,149 shares, equal to 32.6% of shares.
Key metrics
Potential dilution
| CB/BW/EB issued, last 12 months | ₩45.0bn |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 48,288,869 shares |
| Potential new shares, % of shares | 32.6% |
| Conversion price adjustments, last 12 months | 2 |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗